- RecruitingPHASE3
A Study of Sacituzumab Tirumotecan (Sac-TMT, MK-2870) as Monotherapy and in Combination With Pembrolizumab (MK-3475) in Participants With Triple-Negative Breast Cancer (MK-2870-011/TroFuse-011)
This study looks at new treatments, sacituzumab tirumotecan alone or with pembrolizumab, for triple-negative breast cancer. It compares their effectiveness with standard chemotherapy to see if they help people live longer or stop cancer growth.
For: Triple Negative Breast NeoplasmsUnited States · Argentina · Australia - RecruitingPHASE3
A Phase III Study of Dato-DXd With or Without Durvalumab Compared With Investigator's Choice of Chemotherapy in Combination With Pembrolizumab in Patients With PD-L1 Positive Locally Recurrent Inoperable or Metastatic Triple-negative Breast Cancer (TROPION-Breast05)
This study looks at new treatments for a type of breast cancer called triple-negative. It compares a new drug, Dato-DXd, sometimes with Durvalumab, against standard chemotherapy with Pembrolizumab for patients whose cancer has come back locally or spread.
For: Breast CancerUnited States · Argentina · Australia - RecruitingPHASE3
A Study to Assess Efficacy and Safety of Pembrolizumab With or Without Sacituzumab Tirumotecan (MK- 2870) in Adult Participants With Resectable Non Small Cell Lung Cancer (NSCLC) Not Achieving Pathological Complete Response (pCR) (MK-2870-019)
This study is looking at a new treatment for non-small cell lung cancer after surgery. It combines two medicines, sacituzumab tirumotecan and pembrolizumab, to see if they work better together than pembrolizumab alone in preventing the cancer from coming back.
For: Non Small Cell Lung CancerUnited States · Argentina · Australia - RecruitingPHASE1, PHASE2
Phase 1/2 Trial of S241656 in Selected RAS/MAPK Mutation- Positive Malignancies
This study is testing a new medicine called S241656 for people with certain advanced cancers, including lung, bowel, and pancreatic cancers. It aims to find a safe and effective dose, either alone or with other treatments, for cancers with specific genetic changes.
For: Non-small Cell Lung Cancer · Histiocytic Neoplasm · HistiocytosisUnited States · Denmark · Hong Kong - RecruitingPHASE3
ROSETTA Breast-01: The Effects and Safety of Pumitamig in Patients With Triple-Negative Breast Cancer
This study is looking into a new drug called Pumitamig for people with a type of breast cancer called triple-negative breast cancer. It compares Pumitamig plus standard chemotherapy with a dummy drug (placebo) plus chemotherapy to see if it's safe and effective.
For: Breast NeoplasmsUnited States · Australia · Belgium - RecruitingPHASE2
A Master Protocol (LY900023) That Includes Several Clinical Trials of Drugs for Children and Young Adults With Cancer
This study is a research programme looking at new ways to treat cancer in children and young adults aged 1 to 39. It tests different medicines to find out how well they work and if they are safe.
For: Neoplasms · Child · AdolescentUnited States · Australia · Belgium - RecruitingPHASE3
A Three-Part Phase 3 Study of Sofetabart Mipitecan in Participants With Platinum-Resistant (Part A) and Platinum-Sensitive (Parts B and C) Ovarian Cancer
This study is testing a new medicine, Sofetabart Mipitecan, for certain ovarian, fallopian tube, and peritoneal cancers. It aims to see if it works better than current treatments and is safe, for people whose cancer either has or hasn't responded well to previous platinum-based treatments.
For: Ovarian Neoplasms · Fallopian Tube Neoplasms · Peritoneal NeoplasmsUnited States · Australia · Austria - Active not recruitingPHASE3
Durvalumab+ Gemcitabine/Cisplatin (Neoadjuvant Treatment) and Durvalumab (Adjuvant Treatment) in Patients With MIBC
This study looks at a new way to treat muscle-invasive bladder cancer using a drug called Durvalumab alongside standard chemotherapy. It aims to see if this combination, given before and after surgery, can improve treatment outcomes and safety for patients.
For: Muscle Invasive Bladder CancerUnited States · Australia · Belgium - RecruitingPHASE1, PHASE2
A Clinical Study of Raludotatug Deruxtecan in People With Ovarian Cancer (MK-5909-003)
This study looks at new ways to treat ovarian cancer that has come back after earlier treatments. It tests a new drug called Raludotatug deruxtecan (R-DXd) by itself or with other standard treatments, to see if it's safe and helps shrink the cancer.
For: Ovarian Cancer RecurrentUnited States · Canada · Israel - RecruitingPHASE2
AZD0901 in Participants With Advanced Solid Tumours Expressing Claudin18.2
This study is looking at a new medicine called AZD0901 for people with certain advanced cancers like stomach or pancreatic cancer. We want to see how safe it is, if it works, and how the body handles it, sometimes on its own and sometimes with other cancer drugs.
For: Gastric Cancer · Gastroesophageal Junction Cancer · Biliary Tract CancerUnited States · Australia · Canada - RecruitingPHASE2
Using ctDNA to Determine Therapies for Lung Cancer
This study looks at a special blood test for lung cancer. If tiny bits of cancer DNA are found after surgery, researchers want to see if extra treatment can stop the cancer from coming back. It aims to help doctors decide who most needs further treatment.
For: Non Small Cell Lung Cancer · Complete Surgical Resection · Circulating Tumor DNACanada - RecruitingPHASE2
A Study Using Nivolumab, in Combination With Chemotherapy Drugs to Treat Nasopharyngeal Carcinoma (NPC)
This study looks at combining nivolumab, an immunotherapy drug, with chemotherapy and then radiation for young people with nasopharyngeal cancer. Researchers want to see if this new treatment can fight the cancer effectively, understand its side effects, and potentially reduce radiation for children.
For: Stage II Nasopharyngeal Carcinoma AJCC v8 · Stage III Nasopharyngeal Carcinoma AJCC v8 · Stage IV Nasopharyngeal Carcinoma AJCC v8United States · Canada · New Zealand - RecruitingPHASE1
CHemotherapy and Stool Transplant in PDAC (CHASe-PDAC)
This study looks at combining a stool transplant with standard chemotherapy for advanced pancreatic cancer. It's a first step to see if this new combination is safe and how patients respond, hoping to find better ways to treat the disease.
For: Unresectable or Metastatic Advanced Pancreatic Ductal AdenocarcinomaCanada - RecruitingPHASE2
A Study to Evaluate the Optimization of the Cytokine Release Syndrome Profile for Glofitamab in Combination With Gemcitabine Plus Oxaliplatin in Participants With Relapsed/Refractory Aggressive B-Cell Non-Hodgkin's Lymphoma
This study looks at a new way to give a treatment called glofitamab, along with gemcitabine and oxaliplatin, for a type of blood cancer called B-cell non-Hodgkin's lymphoma. The goal is to make the treatment safer and easier to get, potentially as an outpatient.
For: B-Cell Non-Hodgkins LymphomaUnited States · Australia · Canada - Active not recruitingPHASE3
Perioperative Enfortumab Vedotin (EV) Plus Pembrolizumab (MK-3475) Versus Neoadjuvant Chemotherapy for Cisplatin-Eligible Muscle Invasive Bladder Cancer (MIBC) (MK-3475-B15/ KEYNOTE-B15 / EV-304)
This study compares a new drug combination (enfortumab vedotin plus pembrolizumab) with standard chemotherapy for bladder cancer that has spread to the muscle. It aims to see if the new combination, given before surgery, works better and is safe.
For: Bladder CancerUnited States · Argentina · Australia - RecruitingPHASE2
Testing the Addition of BMS-986016 (Relatlimab) to the Usual Immunotherapy After Initial Treatment for Recurrent or Metastatic Nasopharyngeal Cancer
This study looks at adding a new drug, relatlimab, to current treatments for nasopharyngeal cancer that has come back or spread. The aim is to see if this addition can help keep the cancer from growing or spreading for longer.
For: Metastatic Nasopharyngeal Carcinoma · Recurrent Nasopharyngeal Carcinoma · Stage IV Nasopharyngeal Carcinoma AJCC v8United States · Australia · Canada - Active not recruitingPHASE3
Disitamab Vedotin With Pembrolizumab vs Chemotherapy in Previously Untreated Urothelial Cancer Expressing HER2
This study looks at new treatments for bladder and related cancers that have spread. We want to see if combining two drugs, disitamab vedotin and pembrolizumab, works better than standard chemotherapy. It also checks for side effects.
For: Urothelial CarcinomaUnited States · Argentina · Australia - Active not recruitingPHASE3
A Phase-3, Open-Label, Randomized Study of Dato-DXd Versus Investigator's Choice of Chemotherapy (ICC) in Participants With Inoperable or Metastatic HR-Positive, HER2-Negative Breast Cancer Who Have Been Treated With One or Two Prior Lines of Systemic Chemotherapy (TROPION-Breast01)
This study tests a new drug, Dato-DXd, for advanced breast cancer. It compares Dato-DXd to standard chemotherapy in women whose cancer is HR-positive and HER2-negative and has already been treated with other chemotherapy. Researchers want to see if Dato-DXd works better.
For: Breast CancerUnited States · Argentina · Belgium - RecruitingPHASE3
A Study of Duvelisib Versus Gemcitabine or Bendamustine in Participants With Relapsed/Refractory Nodal T Cell Lymphoma With T Follicular Helper (TFH) Phenotype
This study is looking at a new medicine called duvelisib for people in the UK with a specific type of T-cell lymphoma that has come back or not responded to previous treatments. It compares duvelisib to standard treatments like gemcitabine or bendamustine to see if it helps patients live longer without their cancer getting worse.
For: LymphomaBelgium · Czechia · Denmark - RecruitingPHASE2, PHASE3
Phase 2/3 Trial of Izalontamab Brengitecan vs Platinum-based Chemotherapy for Metastatic Urothelial Cancer With Disease Progression on or After Immunotherapy
This study compares a new medicine, Iza-bren, with standard chemotherapy for advanced bladder cancer that has worsened after immunotherapy. It aims to see if Iza-bren is a better option for people who have already had certain treatments for their cancer.
For: Urothelial CancerUnited States · Argentina · Australia - RecruitingPHASE3
Personalized Medicine for Advanced Biliary Cancer Patients
This study looks at whether adding a special "targeted" drug after initial treatment for advanced bile duct cancer works better than continuing standard treatment. It customises treatment based on your tumour's unique features.
For: Biliary Tract NeoplasmsBelgium · France · United Kingdom - Active not recruitingPHASE3
A Study of Subcutaneously Injected Epcoritamab Plus Oral Lenalidomide Tablets Compared to Intravenously (IV) Infused Rituximab Plus IV Infused Gemcitabine and IV Infused Oxaliplatin in Adult Participants With Relapsed or Refractory Diffuse Large B-Cell Lymphoma
This study looks at new treatments for Diffuse Large B-Cell Lymphoma (DLBCL) that has come back or not responded to previous treatment. It compares a new drug called epcoritamab with standard treatments to see which works best and is safest.
For: Diffuse Large B-Cell LymphomaUnited States · Argentina · Australia - RecruitingPHASE2, PHASE3
Study of Nab-Paclitaxel and Gemcitabine With or Without SBP-101 in Pancreatic Cancer
This study is looking into a new treatment called SBP-101 for advanced pancreatic cancer. It combines SBP-101 with standard chemotherapy (nab-paclitaxel and gemcitabine) to see if it helps people live longer and improves their quality of life.
For: Pancreatic Cancer Metastatic · Pancreatic Ductal Adenocarcinoma · Pancreatic Cancer Stage IVUnited States · Australia · Austria - RecruitingPHASE2
Study of Sacituzumab Govitecan in Participants With Urothelial Cancer That Cannot Be Removed or Has Spread
This study looks at new ways to treat bladder cancer that has spread or can't be removed with surgery. It's testing a drug called sacituzumab govitecan, sometimes on its own, and sometimes with other new treatments, to see if they are safe and effective.
For: Metastatic Urothelial CancerUnited States · France · Germany - Active not recruitingPHASE3
Study of MEDI4736 (Durvalumab) With or Without Tremelimumab Versus Standard of Care Chemotherapy in Urothelial Cancer
This study looks at new drug combinations for advanced bladder cancer that hasn't been treated before. It compares them to standard chemotherapy to see if they're safer and work better.
For: Urothelial CancerUnited States · Australia · Austria - RecruitingPHASE3
A Study of Pembrolizumab (MK-3475) With or Without Intismeran Autogene (V940) in Participants With Non-small Cell Lung Cancer (V940-009/INTerpath-009)
This study looks at a new treatment called intismeran autogene, given with pembrolizumab, after surgery for non-small cell lung cancer. We want to see if this combination stops the cancer from coming back compared to pembrolizumab alone.
For: Carcinoma, Non-Small-Cell LungUnited States · Argentina · Australia - Active not recruitingPHASE3
Study to Assess Safety and Efficacy of Atezolizumab (MPDL3280A) Compared to Best Supportive Care Following Chemotherapy in Patients With Lung Cancer [IMpower010]
This study compares a new treatment, Atezolizumab, to standard care for patients with early-stage lung cancer after surgery and chemotherapy. It aims to see if Atezolizumab can prevent the cancer from returning and help people live longer.
For: Non-Small Cell Lung CancerUnited States · Australia · Belgium - RecruitingPHASE2
A Three-arm Randomized Phase II Study of Dostarlimab Alone or With Bevacizumab Versus Nonplatinum Chemotherapy in Recurrent Gynecological Clear Cell Carcinoma: DOVE (APGOT-OV7/ ENGOT-ov80 Study)
This study looks at new treatments (Dostarlimab alone or with Bevacizumab) for certain gynaecological cancers that have come back or not responded to previous treatment, comparing them to standard chemotherapy. It aims to see which treatment works best.
For: Ovarian Neoplasms · Endometrial Neoplasms · Uterine Cervical NeoplasmsAustralia · Hong Kong · Japan - Active not recruitingPHASE3
Study to Assess the Efficacy of Rina-S Compared to Treatment of Investigator's Choice in Participants With Platinum Resistant Ovarian Cancer
This study is testing a new drug called Rina-S for platinum-resistant ovarian cancer. It compares Rina-S to standard chemotherapy treatments. You have an equal chance of receiving Rina-S or a standard chemotherapy. All participants receive active treatment, no placebo.
For: Platinum-resistant Ovarian CancerUnited States · Australia · Austria - Active not recruitingPHASE3
Study of Quemliclustat and Chemotherapy Versus Placebo and Chemotherapy in Patients With Metastatic Pancreatic Ductal Adenocarcinoma
This study is testing a new drug, quemliclustat, alongside standard chemotherapy for pancreatic cancer that has spread. Researchers want to see if adding quemliclustat helps people live longer compared to chemotherapy alone. It's a phase 3 trial, meaning it's in the final stages of testing.
For: Metastatic Pancreatic Ductal AdenocarcinomaUnited States · Australia · Austria - Active not recruitingPHASE2, PHASE3
A Study to Evaluate the Efficacy and Safety of Multiple Targeted Therapies as Treatments for Participants With Non-Small Cell Lung Cancer (NSCLC)
This study looks at new drug combinations for advanced non-small cell lung cancer. It aims to find out how safe and effective these treatments are for people whose cancer has specific genetic changes, using blood tests to identify these changes.
For: Non-Small Cell Lung CancerUnited States · Argentina · Australia - Active not recruitingPHASE3
Study of Sacituzumab Govitecan-hziy Versus Treatment of Physician's Choice in Patients With Previously Untreated Locally Advanced Inoperable or Metastatic Triple-Negative Breast Cancer
This study looks at a new drug, Sacituzumab Govitecan-hziy, for people with an aggressive type of breast cancer called triple-negative breast cancer that has spread or can't be operated on. It compares this new drug to standard treatments to see which works better at stopping the cancer from growing.
For: Triple Negative Breast Cancer · PD-L1 NegativeUnited States · Argentina · Australia - Active not recruitingPHASE3
Study of Sacituzumab Govitecan-hziy and Pembrolizumab Versus Treatment of Physician's Choice and Pembrolizumab in Patients With Previously Untreated, Locally Advanced Inoperable or Metastatic Triple-Negative Breast Cancer
This study is for people with a specific type of advanced breast cancer (PD-L1 positive triple-negative) that hasn't been treated yet. It compares two different drug combinations to see which one works better at stopping the cancer from growing.
For: Triple Negative Breast Cancer · PD-L1 PositiveUnited States · Argentina · Australia - RecruitingPHASE3
Perioperative Durvalumab With Neoadjuvant ddMVAC or Gemcitabine/Cisplatin in Patients With Muscle-invasive Bladder Cancer (NIAGARA-2)
This study, called NIAGARA-2, is looking at a new way to treat bladder cancer that has grown into the muscle. It combines a drug called durvalumab with standard chemotherapy, given before and after surgery. The aim is to see if this combination improves treatment.
For: Urinary Bladder Neoplasms · Immune Checkpoint Inhibitors · MethotrexateAustralia · Brazil · Canada - RecruitingPHASE1
A Study of ASP3082 in Adults With Advanced Solid Tumors
This study looks at a new drug, ASP3082, for adults with advanced solid cancers that have a specific genetic change called KRAS G12D. It checks how safe the drug is and what dose works best, sometimes with another drug called cetuximab.
For: Solid TumorUnited States · China · France - RecruitingPHASE2
Liquid-biopsy Informed Platform Trial to Evaluate CDK4/6-inhibitor Resistant ER+/HER2- Metastatic Breast Cancer
This study looks at new ways to treat advanced breast cancer that has stopped responding to standard treatments. By checking your blood or tumour for specific signs, doctors hope to find the best treatment for you, exploring several new drugs and combinations.
For: Breast CancerCanada - RecruitingPHASE3
Phase 3 Study of T-DXd and Rilvegostomig Versus SoC in Advanced HER2-expressing Biliary Tract Cancer
This study is looking at new treatments for advanced bile duct cancer that has a specific marker called HER2. We want to see if these new medicines work better and are safer than standard treatments for patients who haven't had treatment for their advanced cancer before.
For: Biliary Tract CancerUnited States · Australia · Austria - Active not recruitingPHASE2
A Clinical and Molecular Risk-Directed Therapy for Newly Diagnosed Medulloblastoma
This study looks at new ways to treat medulloblastoma, a type of brain cancer, in children and young adults. It uses a personalised approach, tailoring treatment based on individual tumour features, aiming for better results with fewer side effects.
For: MedulloblastomaUnited States · Australia · Canada - Active not recruitingPHASE3
Trastuzumab Deruxtecan (DS-8201a) Versus Investigator's Choice for HER2-low Breast Cancer That Has Spread or Cannot be Surgically Removed [DESTINY-Breast04]
This study compares a new breast cancer drug, trastuzumab deruxtecan, with standard treatments. It's for people with HER2-low breast cancer that has spread or can't be removed by surgery and who have already had other treatments.
For: Breast CancerUnited States · Austria · Belgium - RecruitingPHASE2
Durvalumab and Tremelimumab in Combination With Propranolol and Chemotherapy for Treatment of Advanced Hepatopancreabiliary Tumors (BLOCKED)
This study looks at combining special medicines called immunotherapy with propranolol, and sometimes chemotherapy, for advanced pancreatic, liver, or bile duct cancers. It aims to see how safe and effective this new treatment approach is for patients.
For: Pancreatic Cancer · Hepatocellular Cancer · Biliary Tract CancerCanada - Active not recruitingPHASE2
Safety, Pharmacokinetics and Clinical Activity of AZD0171 in Combination With Durvalumab and Chemotherapy in Locally Advanced or Metastatic Solid Tumours
This study is looking at a new combination of medicines - AZD0171, durvalumab, and standard chemotherapy - for people with advanced pancreatic cancer. It aims to see how safe and effective this new treatment is.
For: Locally Advanced or Metastatic Solid TumoursUnited States · Canada · South Korea - RecruitingPHASE3
A Study to Evaluate TAR-210 Versus Single Agent Intravesical Cancer Treatment in Participants With Bladder Cancer
This study looks at a new treatment called TAR-210 for a type of bladder cancer. It compares TAR-210 with standard chemotherapy to see which is better at keeping the cancer away.
For: Non-Muscle Invasive Bladder NeoplasmsUnited States · Argentina · Austria - Active not recruitingPHASE2
Gemcitabine Hydrochloride and Cisplatin With or Without Veliparib or Veliparib Alone in Treating Patients With Locally Advanced or Metastatic Pancreatic Cancer
This study looks at new ways to treat pancreatic cancer that has spread. It compares standard chemotherapy with or without a new drug called veliparib. We're testing if adding veliparib helps stop cancer growth, especially in people with specific genetic changes.
For: Locally Advanced Pancreatic Adenocarcinoma · Metastatic Pancreatic Adenocarcinoma · Stage III Pancreatic Cancer AJCC v8United States · Canada · Israel - RecruitingPHASE3
A Study to Evaluate TAR-210 Versus Intravesical Chemotherapy Treatment in Participants With High Risk Non-Muscle-Invasive Bladder Cancer
This study compares a new treatment, TAR-210, with standard chemotherapy for high-risk bladder cancer that hasn't spread to the muscle. It aims to see which treatment best prevents the cancer from returning or getting worse.
For: Non-Muscle Invasive Bladder NeoplasmsUnited States · Argentina · Belgium - RecruitingPHASE3
Neoadjuvant Upper Tract Invasive Cancer Trial (NAUTICAL)
This study looks at treating a rare kidney or ureter cancer with chemotherapy before surgery. It aims to see if this approach, similar to what's done for bladder cancer, can improve outcomes. We're also checking if enough people can join this type of trial.
For: Bladder Cancer · Bladder Urothelial CarcinomaCanada - RecruitingPHASE2
Pembrolizumab and Brentuximab Vedotin vs GDP and Stem Cell Transplant for Relapsed/Refractory Hodgkin Lymphoma
This study looks at new treatments for Hodgkin lymphoma that has returned or not responded to previous treatment. It compares two newer drugs, pembrolizumab and brentuximab vedotin, with the standard treatment to see if they work better.
For: Hodgkin LymphomaAustralia · Canada - Active not recruitingPHASE3
Phase 3 Study of Daraxonrasib (RMC-6236) in Patients With Previously Treated Metastatic Pancreatic Ductal Adenocarcinoma (PDAC)
This study is looking for a new treatment for pancreatic cancer that has spread. It compares a new medicine called RMC-6236 with standard chemotherapy for people whose cancer has already been treated once before. The aim is to see if the new medicine is safer and works better.
For: Pancreatic Cancer · PDAC · PDAC - Pancreatic Ductal AdenocarcinomaUnited States · France · Germany - Not yet recruitingPHASE3
Adjuvant Trial in Patients With Resected PDAC Randomized to Allocation of Oxaliplatin- or Gemcitabine-based Chemotherapy by Standard Clinical Criteria or by a Transcriptomic Treatment Specific Stratification Signature
This study looks at new ways to choose chemotherapy after pancreatic cancer surgery to prevent it from returning. Researchers are comparing standard methods with a new genetic test to see which works best for patients in the UK.
For: Pancreatic Ductal AdenocarcinomaGermany · Sweden - RecruitingPHASE2
Nivolumab in Children and Adults With Nasopharyngeal Carcinoma
This study is looking at adding a new drug called Nivolumab to standard chemotherapy for nasopharyngeal cancer. It aims to see if this combination helps more patients achieve a complete response, meaning the cancer is no longer detectable, especially when seen on scans.
For: Nasopharyngeal Carcinoma · Nasopharyngeal Cancer · Nasopharyngeal NeoplasmsGermany - Active not recruitingPHASE3
Adjuvant Chemotherapy With Gemcitabine and Cisplatin Compared to Standard of Care After Curative Intent Resection of Biliary Tract Cancer
This study looks into a new chemotherapy combination (gemcitabine and cisplatin) compared to the usual care (capecitabine or observation) for people with certain bile duct or gallbladder cancers after surgery. We want to see if the new combination works better.
For: Cholangiocarcinoma · Gall Bladder CarcinomaAustralia · Austria · Denmark